All In Biotech

Drug Trial Radar · NCT04781725

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial

Last checked: Nov 19, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 25, 2021

Primary completion

Mar 1, 2022

Study completion Mar 1, 2023

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Intensity Therapeutics, Inc.; Ontario Institute for Cancer Research
First posted
Mar 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer. In a 2:1 randomization, patients on the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery.

Conditions

  • Breast Cancer

Interventions

  • INT230-6Drug

    INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).

  • Saline injectionOther

    Standard 0.9 % NaCl Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients achieving a CCCA defined as a reduction in the proportion of cells staining positive for Ki67 as assessed by immunohistochemistry to less than a natural logarithm, or ≤2.7%, at the post-treatment specimen.Time frame: presurgical window (period from diagnosis to surgery window of 3-6 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Ottawa Hospital Research Institute and Cancer Center

    Ottawa, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.